Results 111 to 120 of about 697,556 (384)

Enhancing the Pharmacokinetics of Aptamers: Targeting AXL In Vivo Using a Bottlebrush Polymer‐Conjugated Aptamer

Advanced Healthcare Materials, EarlyView.
A phosphodiester‐backboned bottlebrush polymer (pacDNA) engineered for aptamer delivery is presented. This design enhances aptamer stability, plasma pharmacokinetics, and target engagement in vivo. In AXL‐driven cancer models, pacDNA inhibits AXL signaling and reduces tumor growth, highlighting the promise of precision polymer scaffolds in aptamer ...
Tingyu Sun, Jiachen Lin, Chenyang Xue, Yuyan Wang, Peiru Chen, Yun Wei, Guobin Xu, Anais Sidonia, Chris Nenopoulos, Hossam Tashkandi, Caroline Shen, Allison Wang, Alex Wang, Ke Zhang   +13 more
wiley   +1 more source

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

Journal of Clinical Investigation, 1990
Propagation of venous thrombi or rethrombosis after coronary thrombolytic therapy can occur despite heparin administration. To explore potential mechanisms, we set out to determine whether clot-bound thrombin is relatively protected from inhibition by ...
J. Weitz, M. Hudoba, D. Massel, J. Maraganore, J. Hirsh   +4 more
semanticscholar   +1 more source

Heparines

Nursing, 2022
Heparines worden met name ingezet voor de behandeling of profylaxe van diep veneuze trombose of longembolie. Met de toets bij dit artikel verdien je 1 accreditatiepunt.
openaire   +1 more source

Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review [PDF]

, 2017
Study Design: Systematic review. Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another ...
Arnold, Paul M., Casha, Steve, Fehlings, Michael G., Harrop, James S., Holmer, Haley K., Kwon, Brain K., Merli, Geno J., Norvell, Daniel C., Palmieri, Katherine, Tetreault, Lindsay G., Wilson, Jefferson R.   +10 more
core   +2 more sources

High‐Throughput Encapsulation of Stem Cells: Characterizing Dynamic Culture Variability With a Millifluidic Approach

Advanced Healthcare Materials, EarlyView.
A high throughput millifluidic encapsulation platform is engineered and standardized. The system's output allows the monitoring of cell expansion in strong dynamic conditions. High polymer crosslinking leads to higher cell proliferation and lower cell growth on microgel's surface.
Oscar Fabian García‐Aponte, Marta Serra, Simon Kahlenberg, Guruprakash Subbiahdoss, Erik Reimhult, Dominik Egger, Cornelia Kasper   +6 more
wiley   +1 more source

The binding of glycosaminoglycans to peptides : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University [PDF]

, 1994
The overall aim this study was to examine the possibility of using immobilised polypeptide chains to fractionate/separate Glycosaminoglycans (GAG's) from mixtures. Initially individual samples of three GAG classes (chondroitin sulphate, dermatan sulphate
Taylor, Grant John
core  

RBC Membrane‐Camouflaged Nanosystem‐Mediated Synergistic Drug Combination for Enhanced Anti‐Tumor Therapy

Advanced Healthcare Materials, EarlyView.
An RBC membrane camouflaged, cell‐penetrating peptides R8‐based drug delivery system is constructed to achieve a synergistic combination of natural compounds triptolide (TP) and celastrol (Cel), inducing tumor cell apoptosis, reducing tumor metastasis invasion and triggering autophagy disorder in breast cancer and liver cancer.
Qian Cheng, Xuemei Zhong, Lu Deng, Xinling He, Miaoxizi Luo, Ruibing Wang, Jinming Zhang   +6 more
wiley   +1 more source

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

New England Journal of Medicine, 1996
BACKGROUND Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma half-life, better bioavailability after subcutaneous administration, and
M. Levine, M. Gent, J. Hirsh, J. Leclerc, D. Anderson, J. Weitz, Jeffrey S. Ginsberg, A. Turpie, C. Demers, M. Kovacs   +9 more
semanticscholar   +1 more source

Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin: IDENTIFICATION OF THE HEPARIN-BINDING MOTIF OF p17 AS A TARGET FOR THE DEVELOPMENT OF MULTITARGET ANTAGONISTS [PDF]

, 2012
Once released by HIV cells, p17 binds heparan sulfate proteoglycans (HSPGs) and CXCR1 on leukocytes causing their dysfunction. By exploiting an approach integrating computational modeling, site-directed mutagenesis of p17, chemical desulfation of ...
Bugatti, A, Caccuri, F, Caruso, A, Chiodelli, P, D'Ursi, P, Fiorentini, S, Giagulli, C, Milanesi, L, Oreste, P, Orro, A, Rusnati, M, Urbinati, C   +11 more
core   +1 more source